TY - JOUR
T1 - Rhode Island Human Papillomavirus Vaccine School Entry Requirement Using Provider-Verified Report
AU - Thompson, Erika L.
AU - Livingston, Melvin D.
AU - Daley, Ellen M.
AU - Saslow, Debbie
AU - Zimet, Gregory D.
N1 - Funding Information:
These data were derived from (1) U.S. Department of Health and Human Services (DHHS), National Center for Health Statistics, the 2010–2015 National Immunization Survey-Teen, Hyattsville, Maryland: Centers for Disease Control and Prevention, 2011–2016 and (2) U.S. Department of Health and Human Services (DHHS), National Center for Immunization and Respiratory Diseases, the 2016–2017 National Immunization Survey-Teen, Atlanta, Georgia: Centers for Disease Control and Prevention, 2017–2018. GDZ received an honorarium from Sanofi Pasteur for work on the Adolescent Immunization Initiative and an honorarium and travel support from Merck to present at a human papillomavirus vaccine symposium. No other financial disclosures were reported.
Publisher Copyright:
© 2020 American Journal of Preventive Medicine
PY - 2020/8
Y1 - 2020/8
N2 - Introduction: Human papillomavirus vaccine school entry requirements may be an opportunity to improve the low rates of human papillomavirus vaccination among adolescents. This study evaluates changes in provider-verified human papillomavirus vaccine uptake by age 13 years for adolescents in Rhode Island compared with all other states from 2011 to 2017. Methods: The National Immunization Survey-Teen 2011–2017, a population-based cross-sectional survey, was analyzed in 2019. The survey included telephone interviews and provider-verified reports of vaccination among U.S. adolescents aged 13–17 years. The sample was subset to participants with provider-verified human papillomavirus vaccination reports (n=145,153). A difference-in-differences approach evaluated the Rhode Island human papillomavirus vaccination school entry requirement enacted in 2015. The main outcome was provider-verified human papillomavirus vaccine uptake by age 13 years. Results: Compared with boys in other states, boys in Rhode Island had an increase of 14 percentage points in the probability of uptake of human papillomavirus vaccination by age 13 years (β=0.139, 95% CI=0.073, 0.205). No such differences were observed on comparing girls in Rhode Island with girls in other states (β=0.009, 95% CI= −0.068, 0.086). Conclusions: The Rhode Island school entry requirement for human papillomavirus vaccination improved rates of vaccine uptake among boys and may be a useful option for improving human papillomavirus vaccination nationally.
AB - Introduction: Human papillomavirus vaccine school entry requirements may be an opportunity to improve the low rates of human papillomavirus vaccination among adolescents. This study evaluates changes in provider-verified human papillomavirus vaccine uptake by age 13 years for adolescents in Rhode Island compared with all other states from 2011 to 2017. Methods: The National Immunization Survey-Teen 2011–2017, a population-based cross-sectional survey, was analyzed in 2019. The survey included telephone interviews and provider-verified reports of vaccination among U.S. adolescents aged 13–17 years. The sample was subset to participants with provider-verified human papillomavirus vaccination reports (n=145,153). A difference-in-differences approach evaluated the Rhode Island human papillomavirus vaccination school entry requirement enacted in 2015. The main outcome was provider-verified human papillomavirus vaccine uptake by age 13 years. Results: Compared with boys in other states, boys in Rhode Island had an increase of 14 percentage points in the probability of uptake of human papillomavirus vaccination by age 13 years (β=0.139, 95% CI=0.073, 0.205). No such differences were observed on comparing girls in Rhode Island with girls in other states (β=0.009, 95% CI= −0.068, 0.086). Conclusions: The Rhode Island school entry requirement for human papillomavirus vaccination improved rates of vaccine uptake among boys and may be a useful option for improving human papillomavirus vaccination nationally.
UR - http://www.scopus.com/inward/record.url?scp=85084750443&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2020.02.022
DO - 10.1016/j.amepre.2020.02.022
M3 - Article
C2 - 32430223
AN - SCOPUS:85084750443
SN - 0749-3797
VL - 59
SP - 274
EP - 277
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
IS - 2
ER -